BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12402208)

  • 1. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom.
    Borrow R; Goldblatt D; Andrews N; Southern J; Ashton L; Deane S; Morris R; Cartwright K; Miller E
    J Infect Dis; 2002 Nov; 186(9):1353-7. PubMed ID: 12402208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
    de Whalley PC; Snape MD; Kelly DF; Banner C; Lewis S; Diggle L; John TM; Yu LM; Omar O; Borkowski A; Pollard AJ
    Pediatr Infect Dis J; 2011 Nov; 30(11):e203-8. PubMed ID: 21673612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.
    Richmond P; Borrow R; Findlow J; Martin S; Thornton C; Cartwright K; Miller E
    Infect Immun; 2001 Apr; 69(4):2378-82. PubMed ID: 11254596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children.
    Borrow R; Goldblatt D; Andrews N; Richmond P; Southern J; Miller E
    J Infect Dis; 2001 Aug; 184(3):377-80. PubMed ID: 11443568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom.
    Auckland C; Gray S; Borrow R; Andrews N; Goldblatt D; Ramsay M; Miller E
    J Infect Dis; 2006 Dec; 194(12):1745-52. PubMed ID: 17109348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
    Perrett KP; Winter AP; Kibwana E; Jin C; John TM; Yu LM; Borrow R; Curtis N; Pollard AJ
    Clin Infect Dis; 2010 Jun; 50(12):1601-10. PubMed ID: 20459323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age.
    Ishola DA; Andrews N; Waight P; Yung CF; Southern J; Bai X; Findlow H; Matheson M; England A; Hallis B; Findlow J; Borrow R; Miller E
    Pediatr Infect Dis J; 2015 Aug; 34(8):865-74. PubMed ID: 26075813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
    Zhang Q; Lakshman R; Burkinshaw R; Choo S; Everard J; Akhtar S; Finn A
    Infect Immun; 2001 Jul; 69(7):4337-41. PubMed ID: 11401971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.
    Richmond P; Borrow R; Goldblatt D; Findlow J; Martin S; Morris R; Cartwright K; Miller E
    J Infect Dis; 2001 Jan; 183(1):160-3. PubMed ID: 11078484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
    Southern J; Deane S; Ashton L; Borrow R; Goldblatt D; Andrews N; Balmer P; Morris R; Kroll JS; Miller E
    Clin Diagn Lab Immunol; 2004 Nov; 11(6):1100-4. PubMed ID: 15539513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination.
    Perrett KP; Richmond PC; Borrow R; Nolan T; McVernon J
    Pediatr Infect Dis J; 2015 Mar; 34(3):279-85. PubMed ID: 25742078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool.
    Stoof SP; van der Klis FR; van Rooijen DM; Bogaert D; TrzciƄski K; Sanders EA; Berbers GA
    Vaccine; 2015 Jul; 33(32):3933-9. PubMed ID: 26100925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers.
    Booy R; Richmond P; Nolan T; McVernon J; Marshall H; Nissen M; Reynolds G; Ziegler JB; Stoney T; Heron L; Lambert S; Mesaros N; Peddiraju K; Miller JM
    Pediatr Infect Dis J; 2013 Feb; 32(2):169-74. PubMed ID: 23080288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine.
    Borrow R; Fox AJ; Richmond PC; Clark S; Sadler F; Findlow J; Morris R; Begg NT; Cartwright KA
    Epidemiol Infect; 2000 Jun; 124(3):427-32. PubMed ID: 10982066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune memory in children previously vaccinated with an experimental quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine.
    Pichichero M; Papa T; Blatter M; Mitchell D; Kratz R; Sneed J; Bassily E; Casey J; Gilmet G
    Pediatr Infect Dis J; 2006 Nov; 25(11):995-1000. PubMed ID: 17072120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children.
    McVernon J; Maclennan J; Buttery J; Oster P; Danzig L; Moxon ER
    Pediatr Infect Dis J; 2002 Aug; 21(8):747-53. PubMed ID: 12192163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age.
    Al-Mazrou Y; Khalil M; Borrow R; Balmer P; Bramwell J; Lal G; Andrews N; Al-Jeffri M
    Infect Immun; 2005 May; 73(5):2932-9. PubMed ID: 15845499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.
    Borrow R; Andrews N; Goldblatt D; Miller E
    Infect Immun; 2001 Mar; 69(3):1568-73. PubMed ID: 11179328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of serogroup C antibody responses following quadrivalent meningococcal conjugate vaccination in United States military personnel.
    Patel M; Romero-Steiner S; Broderick MP; Thomas CG; Plikaytis BD; Schmidt DS; Johnson SE; Milton AS; Carlone GM; Clark TA; Messonnier NE; Cohn AC; Faix DJ
    Vaccine; 2014 Jun; 32(30):3805-9. PubMed ID: 24837781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.